Share

Save

PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours

PHASE1RECRUITING

This phase 1 dose-escalation study is designed to evaluate the safety and tolerability of talazoparib in combination with 177Lu-DOTA-Octreotate peptide receptor radionuclide therapy (PRRT) in patients with metastatic pancreatic or midgut neuroendocrine tumour (NET).

info
Simpliy with AI

Study details:

This phase 1, single arm, single centre study is designed to evaluate the safety and tolerability of talazoparib in combination with 177Lu-DOTA-Octreotate in patients with metastatic NET. Patients will receive 1 cycle of 177Lu-DOTA-Octreotate alone followed by 3 cycles of 177Lu-DOTA-Octreotate combined with 5 days of talazoparib.

info
Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

  • Patient must be > or equal to 18 years of age and must have provided written informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
  • Histologically confirmed Grade 2 NET, Ki-67 of 3-20%, from pancreatic or intestinal origin.
  • Patient clinically suitable for PRRT
  • Tumor SSR uptake on GaTate PET/CT higher than liver activity, ≥ modified Krenning 3 score
  • No discordant FDG-avid disease on FDG PET/CT
  • No evidence of significant uncorrected carcinoid heart disease
  • Patients must be willing and able to comply with the protocol for the duration of the study including undergoing treatment, scheduled assessments
  • Patients must have adequate bone marrow, hepatic and renal function defined as: Haemoglobin ≥100 g/L, Absolute neutrophil count ≥1.5x109/L, Platelets ≥150 x109/L, Total bilirubin ≤1.5 x upper limit of normal (ULN), Aspartate transaminase (AST) (SGOT) and alanine transaminase (ALT) (SGPT) ≤2.5 x ULN if there is no evidence of liver metastasis or ≤5 x ULN in the presence of liver metastases, Albumin ≥ 30 g/L, Adequate renal function: eGFR ≥ 60 ml/min
  • Exclusion criteria

  • Surgery or radiotherapy within <3 weeks of registration. Patients must have recovered from any effects of any major surgery.
  • Any prior exposure to peptide receptor radionuclide therapy (177Lu, 111In or 90Y labelled), PARPi, immunotherapy
  • Uncontrolled intercurrent illness that is likely to impede participation and /or compliance
  • Other malignancies unless curatively treated with no evidence of disease within previous 3-years other than adequately treated non-melanoma skin cancer or melanoma in situ.
  • Previous or current history of myelodysplastic syndrome/acute myeloid leukemia
  • Patients unable to swallow orally administered medications or with gastrointestinal disorders likely to interfere with the absorption of the study medication.
  • Use of strong P-gp inhibitors (eg, dronedarone, quinidine, ranolazine, verapamil, ketoconazole, itraconazole), P-gp inducers (eg, rifampin, tipranavir/ritonavir), or BCRP inhibitors (eg, elacridar [GF120918]) should be avoided.
  • Participation in another clinical study with an investigational product or another systemic therapy administered in the last 3 weeks (except short acting SSA).
  • info
    Simplify with AI

    Eligibility

    Age eligible for study : 18 and older

    Healthy volunteers accepted : No

    Gender eligible for study: All

    Things to know

    Study dates

    Study start: 2021-12-08

    Primary completion: 2029-06-30

    Study completion finish: 2029-06-30

    study type

    Study type

    TREATMENT

    phase

    Phase

      PHASE1

    trial

    Trial ID

    NCT05053854

    Intervention or treatment

    DRUG: Talazoparib

    Conditions

    • Neuroendocrine Tumors

    Find a site

    Closest Location:

    Peter MacCallum Cancer Centre

    Research sites nearby

    Select from list below to view details:

    • Peter MacCallum Cancer Centre

      Melbourne, Victoria, Australia

    Loading...

    Study Plan

    This section provides details of the study plan, including how the study is designed and what the study is measuring.

    How is the study designed?

    Participant Group/ArmIntervention/Treatment
    EXPERIMENTAL: 177Lu-DOTA-Octreotate + talazoparib
    • Patients will receive 4 cycles of 177Lu-DOTA-Octreotate every 8 weeks, the last 3 cycles combined with talazoparib on days 2-6 of each cycle.
    DRUG: Talazoparib
    • During dose escalation, doses of talazoparib that can be administered are 0.1mg, 0.25mg, 0.5mg or 1mg oral daily. Talazoparib will be given on days 2-6 of each cycle of 177Lu-DOTA-Octreotate for cycles 2-4, every 8 weeks

    What is the study measuring?

    Primary outcome

    Primary Outcome MeasurePrimary Outcome DescriptionPrimary Outcome Time Frame
    Maximum tolerated dose Talazoparib with 177Lu-DOTA-OctreotateMaximum tolerated dose of Talazoparib when given in combination with 177Lu-DOTA-OctreotateThrough study completion, up to 18 months following first administration of PRRT.
    Dose limiting toxicity talazoparibThe toxicity (haematologic or non-haematologic) that prevents further administration of the trial talazoparib treatment at that dose level.Each cohort of 3 patients be assessed for DLTs in the first 6 weeks (cycle 2) of treatment and a dose for the next cohort will be determined (each cycle is 8 weeks)

    Secondary outcome

    Secondary Outcome MeasureSecondary Outcome DescriptionSecondary Outcome Time Frame
    Adverse Events and Serious Adverse Events measured using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0Safety of the combination will be measured by AEs and SAEsThrough Study completion, up to 18 months after the last patient commences treatment.
    Radiographic progression free survivalThe time from treatment initiation to the first date of progression on imaging or death due to any cause. Imaging progression will be assessed by RECIST 1.1. Patients who commence new systemic therapy before evidence of disease progression on conventional imaging will be considered to have progressed.Through study completion, up to 18 months following first administration of PRRT.
    Overall SurvivalThe time from treatment initiation to the date of death due to any cause. For patients alive, the time will be censored at the last time the patients was known to be alive.Through study completion, up to 18 months following first administration of PRRT.
    Treatment discontinuation due to toxicityThe number of patients who discontinue treatment at any time due to treatment related toxicity will be reported and will be also categorised by dose level.Through study completion, up to 18 months following first administration of PRRT.
    Rate of Treatment discontinuation due to toxicityThe percentage of patients who discontinue treatment due to treatment related toxicity will be reported and will be also categorised by dose levelThrough study completion, up to 18 months following first administration of PRRT.

    Frequently Asked Questions

    Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

    No questions submitted. Be the first to ask a question!

    You may be eligible to participate in this trial based on your search.Apply for study
    Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

    References

    Clinical Trials Gov: PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours

    Other trails to consider

    Top searched conditions